As of July 23, 2026, the US had confirmed 2,318 measles cases, surpassing the full-year 2025 total (2,289) and marking the highest count since 1991. Ninety-three percent of 2026 cases are ...
Jon Farber, MD, shares his thoughts on the diagnosis of slipped capital femoral epiphysis. The diagnosis of slipped capital femoral epiphysis (SCFE) in children whose presenting symptom is knee pain ...
Jon Farber, MD, shares his thoughts on the efficacy of laser therapy for temporal lobe epilepsy. A retrospective study in 19 children with mesial temporal lobe epilepsy who underwent laser ...
Serial amnioinfusions enabled lung development and live birth in most pregnancies complicated by fetal renal failure and anhydramnios. Survival beyond birth remains dependent on intensive neonatal ...
Individualized antisense oligonucleotide therapy was associated with reduced seizure burden and developmental gains in 2 children with SCN2A-related developmental epileptic encephalopathy.
Outdoor meals raise the risk of food poisoning. Here's how families can keep picnics, cookouts and beach days food-safe, from coolers to grill temperatures. Summer means more meals outside — at the ...
A look back at the FDA approvals, regulatory decisions, and pipeline updates in the pediatric health care space from June 2026. Another month has come and gone, and with it, several FDA approvals and ...
New AAP guidance recommends age-specific iron deficiency screening, updated ferritin thresholds, and simplified treatment strategies for children. Iron deficiency remains one of the most common ...
The FDA has accepted Pharvaris's NDA for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand HAE attack treatment, with a PDUFA date of April 23, 2027. In the Phase 3 RAPIDe-3 ...
VCA-894A received FDA rare pediatric disease designation for CMT2S, an ultrarare inherited neuropathy with limited treatment options. The FDA has granted rare pediatric disease designation to VCA-894A ...
A look back at the latest clinical trial updates for the pediatric population during June 2026. June brought a more concentrated set of clinical trial developments than earlier in the quarter, with ...
Tegacorat received FDA orphan drug and rare pediatric disease designations for Duchenne muscular dystrophy. The FDA has granted orphan drug and rare pediatric disease designations to tegacorat (GRM-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results